Journal article icon

Journal article

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Abstract:

BACKGROUND: Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate. METHODS: In an interna...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


St Clair, EW More by this author
Breedveld, F More by this author
Expand authors...
Journal:
Lancet
Volume:
354
Issue:
9194
Pages:
1932-1939
Publication date:
1999-12-05
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
URN:
uuid:e2ea3470-c8b2-418c-a908-b10ccaba93fa
Source identifiers:
481573
Local pid:
pubs:481573

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP